Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa

Robert Sabat*, Johann Eli Gudjonsson, Nicolo Costantino Brembilla, Kelsey R. van Straalen, Kerstin Wolk

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)


Skin disorders affect *40% of the human population. One of the most debilitating cutaneous disorders is Hidradenitis suppurativa (HS), a noncommunicable chronic inflammatory disease with an estimated global prevalence of 0.4% to 2.5%. In January 2011, high levels of IL-17 were discovered in skin lesions of HS patients. In the following years, translational and clinical research led to a better understanding of the pathogenesis of HS. In June 2023, more than 12 years after the initial note, secukinumab, an anti-IL-17A monoclonal antibody, was approved for the treatment of moderate to severe HS. This is the next milestone in improving the treatment of these patients after the approval of the anti-TNF-a monoclonal antibody adalimumab in 2015. In this review article, we present the IL-17 pathway in HS and discuss the use of secukinumab as a therapeutic option for this disease. Our review starts with a description of the epidemiology, clinical features, etiology, and pathogenesis of HS. An overview of the IL-17/IL-17 receptor system in general and a detailed description of the known facts about the expression and action of IL-17 in HS follow. Afterward, we consider the results of clinical trials evaluating the safety and efficacy of IL-17 inhibitors in HS. Finally, a comparison is made between secukinumab and adalimumab and the characteristics of the patients that may be particularly suitable for each of these biologics are described.

Original languageEnglish
Pages (from-to)544-556
Number of pages13
JournalJournal of Interferon and Cytokine Research
Issue number12
Early online date12 Oct 2023
Publication statusPublished - 1 Dec 2023

Bibliographical note

Publisher Copyright:
© Mary Ann Liebert, Inc.


Dive into the research topics of 'Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa'. Together they form a unique fingerprint.

Cite this